Traditional Chinese medicine Ka-Sai-Ping suppresses the growths of gastric cancers via induction of autophagy
Metrics: PDF 6188 views | HTML 1531 views | ?
Mo-Li Zhu1,*, Jun-Xiu Lu2,*, Guo-Pin Pan1, Song Ping1, Fan-Rong Zhao3, Heng-Tian Qi4, Hai-Ya Yu5, Xu Jian1, Guang-Rui Wan1 and Peng Li1
1College of Pharmacy, Xinxiang Medical University, Xinxiang, China
2Department of Histology and Embryology, Xinxiang Medical University, Xinxiang, China
3San-Quan College of Xinxiang Medical University, Xinxiang, China
4Department of Cardiothoracic Surgery, The Third Affiliated Hospital, Xinxiang Medical University, Xinxiang, China
5Department of Neurology, The People’s Hospital of Xishui County, Huangang, Hubei, China
*These authors contributed equally to this work
Peng Li, email: email@example.com
Keywords: traditional Chinese medicine, Ka-Sai-Ping, gastric cancer, autophagy, apoptosis
Received: March 17, 2017 Accepted: May 10, 2017 Published: May 20, 2017
Traditional Chinese medication is increasingly used to treat a wide range of human chronic diseases like cardiovascular diseases and cancers. This study was designed to explore whether ka-sai-ping (KSP), a novel traditional Chinese medicine developed by us, prevents gastric cancer growths and to investigate the underlying mechanism. The xenograft model of mouse gastric cancer was established by injecting MFCs into nude mouse subcutaneously. Cell autophagy was assessed by MDC staining. Lysosome and mitochondria were detected by Lyso-Tracker Red and Mito-Traker Green staining. Incubation of cultured mouse gastric cancer cell line MFCs with KSP for 48 hours, concentration-dependently reduced cell survivals and activated autophagy, which were accompanied with damaged lysosomes and mitochondria. In vivo studies indicated that KSP therapy (20 ml/kg/day) for two weeks suppressed the growth of gastric cancer, increased the protein levels of LC3-II, beclin-1, cathepsin L, bcl-2, p53, and capase-3 in tumor tissues from the xenograft model of mouse gastric cancer. Importantly, all these effects induced by KSP were abolished by co-administration of autophagy inhibitor 3-MA. In conclusion, KSP activates cell autophagy to suppress gastric cancer growths. Clinically, KSP is potentially considered as a medicine to treat patients with gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.